<DOC>
	<DOCNO>NCT03093402</DOCNO>
	<brief_summary>One hundred adult active joint disease least moderate pain enrol study evaluate JBT-101 , synthetic endocannabinoid receptor type 2 ( CB2 ) agonist activator body 's normal process , resolve innate immune response without immunosuppression . Participants receive 2 dos mouth JBT-101 ( three group vary dos ) placebo 84 day continue follow additional 28 day . Participant visit assess endpoint occur Day 1 , every 2 week twice , every 4 week three time , total six visit . The change maximum daily pain Numerical Rating Scale ( NRS ) score Baseline ( Visit 1 ) assess every visit . Studies also plan evaluate tolerability inflammation .</brief_summary>
	<brief_title>JBT-101 Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Fulfills updated American College Rheumatology ( ACR ) 1982 Revised Criteria Classification Systemic Lupus Erythematosus ; At least 3 month treatment antimalarial drug hydroxychloroquine history intolerance , contraindication , unwillingness take antimalarial drug ; Meets Safety Estrogen Lupus : National Assessment ( SELENA ) Systemic Lupus Erythematosus Disease Activity Index ( SLEDAI ) definition arthritis ( Petri et al. , 1999 ) mild/moderate arthritis tendonitis score BILAG B update BILAG 2004 ; Sevenday average maximum daily pain Numerical Rating Scale ( NRS ) score ≥ 4 10 ; Overlap polymyositis , systemic sclerosis , Sjögren 's syndrome , rheumatoid arthritis allow , , site investigator 's judgment , predominant clinical feature Systemic Lupus Erythematosus ( SLE ) ; Not expect site investigator require change potential disease modify treatment SLE Screening Visit 6 ( Day 112 ) ; Willing start stop NonSteroidal AntiInflammatory Drugs ( NSAIDs ) potential diseasemodifying medication supplement SLE Screening Visit 6 ( Day 112 ) , unless change recommend site investigator treat physician ; Willing use legal illegal cannabinoids , include Food Drug Administration ( FDA ) approve cannabinoids cannabinoidmimic drug , illegal substance abuse Screening Visit 6 ( Day 112 ) ; If woman childbearing potential , willing use one highly effective ( failure rate &lt; 1 % per year ) birth control method Screening Visit 6 ( Day 112 ) 28 ± 3 day last dose study product ; Willing follow instruction , complete study procedure attend study visit require protocol . Severe unstable Systemic lupus erythematosus ( SLE ) , one following : A British Isles Lupus Activity Group ( BILAG ) A score one BILAG domains Screening ; Treatment intraarticular , intravenous , intramuscular systemic corticosteroid &gt; 10 mg per day &gt; 20 mg every day oral prednisone equivalent dose another corticosteroid increase dose systemic corticosteroid 14 day prior assessment 7day average maximum daily pain NRS score Screening 28 day prior Visit 1 ( Day 1 ) ; Treatment cyclophosphamide antiTNFalpha biologic agent within 3 month Visit 1 ( Day 1 ) ; Treatment B celldepleting monoclonal antibody ( rituximab , Ocrelizumab , antiCD22 ) within 6 month Visit 1 ( Day 1 ) ; Treatment methotrexate , mycophenolate , azathioprine , leflunomide , cyclosporine , belimumab , tacrolimus , immunosuppressive agent include 2b.d . , dose immunosuppressive agent increase within 3 month Visit 1 . Concurrent treatment medication allow long dos stable least 3 month Visit 1 ( Day 1 ) ; Actively list organ transplantation list receive organ transplant corneal transplant . Significant disease condition SLE may influence response study product safety , : Active bacterial viral infection require systemic antibiotic antiviral treatment within 14 day Visit 1 ( Day 1 ) ; Acute chronic hepatitis B C infection ; Human immunodeficiency infection ( HIV ) ; History active tuberculosis positive tuberculosis skin blood test without : 1 ) complete course appropriate treatment ; ) receive least one month appropriate treatment prior Visit 1 ( Day 1 ) continue receive appropriate treatment study ; No elective surgery plan Visit 1 ( Day 1 ) Visit 6 ( Day 112 ) ; A history cancer except basal cell carcinoma situ carcinoma cervix treat apparent success curative therapy great one year Visit 1 ( Day 1 ) . Significant heart disease define : Uncontrollable congestive heart failure , unstable angina , unstable atherosclerotic cardiovascular disease , significant arrhythmia require chronic therapy , pulmonary arterial hypertension dyspnea , disability rat New York heart Association Grade III high , severe systemic hypertension severe peripheral vascular disease ; Marked baseline prolongation QT/QTc interval ( i.e . repeat demonstration QTc interval ≥ 450 msec male ≥470 msec female ) ; History risk factor torsade de pointes ( e.g. , heart failure , hypokalemia , family history long QT/QTc syndrome ) ; Clinically significant confirm abnormality , determine site investigator qualify designee , 12lead Electrocardiogram ( ECG ) Screening Visit 1 ( Day 1 ) dosing . History chronic pain require treatment narcotic analgesia 14 day total within 6 month baseline . This include selflimited pain associate identifiable event surgery ; Current evidence alcohol abuse ( define 4 drink per day least 4 day week ) history abuse illegal and/or legally prescribe drug barbiturate , benzodiazepine , amphetamine , cocaine , opioids 1 year prior Screening ; Currently pregnant , breastfeed , lactate ; Any investigational agent within 30 day five therapeutic halflives agent whichever longer , Visit 1 ( Day 1 ) ; Any follow value laboratory test Screening : A positive pregnancy test ( also Visit 1 ) ; A newly positive QuantiFERON ( R ) blood test tuberculosis , without : 1 ) complete course appropriate treatment ; ) receive least one month appropriate treatment prior Visit 1 continue receive appropriate treatment study . If subject previous document positive tuberculosis skin , test need repeat . If subject document negative test result within last year , test need repeat , discretion site investigator . Hemoglobin &lt; 8 g/dL ; Neutrophils &lt; 1.0 x 10^9/L ; Platelets &lt; 75 x 10^9/L ; Creatinine clearance &lt; 50 ml/min accord modify CockcroftGault equation : Creatinine clearance = [ weight ( kg ) x ( 140 age ) /72 x serum creatinine concentration ] x male : x 1 , female : × 0.85 ; Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase &gt; 2.0 x upper limit normal ; Total bilirubin ≥ 1.5 x upper limit normal . Any condition , opinion site investigator , clinically significant may put subject great safety risk , influence response study product , interfere study assessment . When doubt , site investigator qualify designee discuss situation Protocol Chairs .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>JBT-101</keyword>
	<keyword>SLE</keyword>
	<keyword>efficacy</keyword>
	<keyword>musculoskeletal disease</keyword>
	<keyword>randomize trial</keyword>
</DOC>